Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Latz

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Chemical Immunology|December 23, 1999
Lipopolysaccharide-binding proteinR R Schumann, E Latz
Cancer Chemotherapy and Pharmacology|December 3, 2005
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patientsJane E Latz, Ajai Chaudhary, Atalanta Ghosh, et al.
The American Journal of Gastroenterology|July 1, 1989
Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study GroupJ A Cherner, M L Cloud, W W Offen, et al.
British Journal of Pharmacology|August 14, 2014
IL-1β and IL-18: inflammatory markers or mediators of hypertension?S M Krishnan, C G Sobey, E Latz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patientsJane E Latz, Karen Lee Schneck, Kazuhiko Nakagawa, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2005
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapyJane E Latz, Mats O Karlsson, James J Rusthoven, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2005
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapyJane E Latz, James J Rusthoven, Mats O Karlsson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumorsJ L Misset, E Gamelin, M Campone, et al.
British Journal of Cancer|August 31, 2006
A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumoursK Nakagawa, S Kudoh, K Matsui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancerNicolas J Dickgreber, Thomas H Fink, Jane E Latz, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Chemical Immunology|December 23, 1999
Lipopolysaccharide-binding proteinR R Schumann, E Latz
Cancer Chemotherapy and Pharmacology|December 3, 2005
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patientsJane E Latz, Ajai Chaudhary, Atalanta Ghosh, et al.
The American Journal of Gastroenterology|July 1, 1989
Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study GroupJ A Cherner, M L Cloud, W W Offen, et al.
British Journal of Pharmacology|August 14, 2014
IL-1β and IL-18: inflammatory markers or mediators of hypertension?S M Krishnan, C G Sobey, E Latz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patientsJane E Latz, Karen Lee Schneck, Kazuhiko Nakagawa, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2005
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapyJane E Latz, Mats O Karlsson, James J Rusthoven, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2005
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapyJane E Latz, James J Rusthoven, Mats O Karlsson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumorsJ L Misset, E Gamelin, M Campone, et al.
British Journal of Cancer|August 31, 2006
A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumoursK Nakagawa, S Kudoh, K Matsui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancerNicolas J Dickgreber, Thomas H Fink, Jane E Latz, et al.
Pageof 3